FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2076456688> ?p ?o ?g. }

• W2076456688 endingPage "939" @default.
• W2076456688 startingPage "929" @default.
• W2076456688 abstract "We undertook this study to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of LY2439821, a humanized anti-interleukin-17 (anti-IL-17) monoclonal antibody, in a first in-human trial in rheumatoid arthritis (RA) patients taking oral disease-modifying antirheumatic drugs (DMARDs).This randomized, double-blind, placebo-controlled study consisted of 2 parts. In part A, 20 patients received 1 intravenous (IV) dose of LY2439821 (0.06, 0.2, 0.6, or 2.0 mg/kg, escalating) or placebo followed by 8 weeks of evaluation. End points included safety, tolerability, and pharmacokinetics. In part B, 77 patients received 1 IV dose of LY2439821 (0.2, 0.6, or 2.0 mg/kg) or placebo every 2 weeks for a total of 5 doses, with a total evaluation period of 16 weeks. End points included safety, tolerability, pharmacokinetics/pharmacodynamics, and efficacy (Disease Activity Score in 28 joints [DAS28] and percentages of patients meeting American College of Rheumatology 20%, 50%, or 70% improvement criteria [achieving an ACR20, ACR50, or ACR70 response]). The primary efficacy end point was the DAS28 at week 10.Baseline characteristics were similar across all groups. Changes in the DAS28 were significantly greater in the 0.2 mg/kg, 2.0 mg/kg, and all-LY2439821-combined groups (-2.3, -2.4, and -2.3, respectively) than in the placebo group (-1.7) at week 10 (P < or = 0.05), and these differences were significant as early as week 1. Percentages of ACR20, ACR50, and ACR70 responses as well as improvements in the ACR core set of measures were greater in LY2439821-treated patients than in placebo-treated patients at multiple time points. There was no apparent dose-response relationship in treatment-emergent adverse events.LY2439821 added to oral DMARDs improved signs and symptoms of RA, with no strong adverse safety signal noted. This first evaluation of LY2439821 supports neutralization of IL-17 as a potential novel goal for the treatment of RA." @default.
• W2076456688 created "2016-06-24" @default.
• W2076456688 creator A5003819213 @default.
• W2076456688 creator A5010604691 @default.
• W2076456688 creator A5021278814 @default.
• W2076456688 creator A5033983216 @default.
• W2076456688 creator A5059854352 @default.
• W2076456688 creator A5067996280 @default.
• W2076456688 creator A5083311199 @default.
• W2076456688 date "2010-01-21" @default.
• W2076456688 modified "2023-10-02" @default.
• W2076456688 title "LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I randomized, double-blind, placebo-controlled, proof-of-concept study" @default.
• W2076456688 cites W1533030532 @default.
• W2076456688 cites W1553271826 @default.
• W2076456688 cites W1702969026 @default.
• W2076456688 cites W1970577585 @default.
• W2076456688 cites W1985004174 @default.
• W2076456688 cites W1987032872 @default.
• W2076456688 cites W1997007445 @default.
• W2076456688 cites W2001857046 @default.
• W2076456688 cites W2009840473 @default.
• W2076456688 cites W2033299724 @default.
• W2076456688 cites W2079494090 @default.
• W2076456688 cites W2081734937 @default.
• W2076456688 cites W2092602103 @default.
• W2076456688 cites W2110177517 @default.
• W2076456688 cites W2111421688 @default.
• W2076456688 cites W2136357996 @default.
• W2076456688 cites W2152348310 @default.
• W2076456688 cites W2159106700 @default.
• W2076456688 cites W2160258620 @default.
• W2076456688 cites W2160883911 @default.
• W2076456688 cites W2180940175 @default.
• W2076456688 cites W334564628 @default.
• W2076456688 cites W4241917186 @default.
• W2076456688 cites W4361867558 @default.
• W2076456688 doi "https://doi.org/10.1002/art.27334" @default.
• W2076456688 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20131262" @default.
• W2076456688 hasPublicationYear "2010" @default.
• W2076456688 type Work @default.
• W2076456688 sameAs 2076456688 @default.
• W2076456688 citedByCount "437" @default.
• W2076456688 countsByYear W20764566882012 @default.
• W2076456688 countsByYear W20764566882013 @default.
• W2076456688 countsByYear W20764566882014 @default.
• W2076456688 countsByYear W20764566882015 @default.
• W2076456688 countsByYear W20764566882016 @default.
• W2076456688 countsByYear W20764566882017 @default.
• W2076456688 countsByYear W20764566882018 @default.
• W2076456688 countsByYear W20764566882019 @default.
• W2076456688 countsByYear W20764566882020 @default.
• W2076456688 countsByYear W20764566882021 @default.
• W2076456688 countsByYear W20764566882022 @default.
• W2076456688 countsByYear W20764566882023 @default.
• W2076456688 crossrefType "journal-article" @default.
• W2076456688 hasAuthorship W2076456688A5003819213 @default.
• W2076456688 hasAuthorship W2076456688A5010604691 @default.
• W2076456688 hasAuthorship W2076456688A5021278814 @default.
• W2076456688 hasAuthorship W2076456688A5033983216 @default.
• W2076456688 hasAuthorship W2076456688A5059854352 @default.
• W2076456688 hasAuthorship W2076456688A5067996280 @default.
• W2076456688 hasAuthorship W2076456688A5083311199 @default.
• W2076456688 hasConcept C111113717 @default.
• W2076456688 hasConcept C112705442 @default.
• W2076456688 hasConcept C126322002 @default.
• W2076456688 hasConcept C142724271 @default.
• W2076456688 hasConcept C168563851 @default.
• W2076456688 hasConcept C197934379 @default.
• W2076456688 hasConcept C198451711 @default.
• W2076456688 hasConcept C203092338 @default.
• W2076456688 hasConcept C204787440 @default.
• W2076456688 hasConcept C27081682 @default.
• W2076456688 hasConcept C2777575956 @default.
• W2076456688 hasConcept C2778375690 @default.
• W2076456688 hasConcept C71924100 @default.
• W2076456688 hasConcept C90924648 @default.
• W2076456688 hasConcept C98274493 @default.
• W2076456688 hasConceptScore W2076456688C111113717 @default.
• W2076456688 hasConceptScore W2076456688C112705442 @default.
• W2076456688 hasConceptScore W2076456688C126322002 @default.
• W2076456688 hasConceptScore W2076456688C142724271 @default.
• W2076456688 hasConceptScore W2076456688C168563851 @default.
• W2076456688 hasConceptScore W2076456688C197934379 @default.
• W2076456688 hasConceptScore W2076456688C198451711 @default.
• W2076456688 hasConceptScore W2076456688C203092338 @default.
• W2076456688 hasConceptScore W2076456688C204787440 @default.
• W2076456688 hasConceptScore W2076456688C27081682 @default.
• W2076456688 hasConceptScore W2076456688C2777575956 @default.
• W2076456688 hasConceptScore W2076456688C2778375690 @default.
• W2076456688 hasConceptScore W2076456688C71924100 @default.
• W2076456688 hasConceptScore W2076456688C90924648 @default.
• W2076456688 hasConceptScore W2076456688C98274493 @default.
• W2076456688 hasIssue "4" @default.
• W2076456688 hasLocation W20764566881 @default.
• W2076456688 hasLocation W20764566882 @default.
• W2076456688 hasOpenAccess W2076456688 @default.
• W2076456688 hasPrimaryLocation W20764566881 @default.
• W2076456688 hasRelatedWork W1830687917 @default.

• next